Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)

Part of paid clinical trials in Las Vegas, Nevada.

Sponsor
Center for Sight Las Vegas
Study ID
NCT07281950
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Dry Eye Disease (DED)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • acoltremon 0.003% — DRUG
    single arm

Study Details

Dry eye disease (DED) is a common, chronic and multifactorial disease of the ocular surface presenting with signs and symptoms of ocular discomfort, visual disturbance and fluctuation, tear film instability, ocular surface inflammation and damage. It significantly affects patients' quality of life and is one of the most frequent reasons for visits to eye care providers. Many patients remain symptomatic in real-world settings despite current pharmacologic therapeutic options available. As symptoms often lag behind ocular signs, a 3 month study with multiple time points has been designed to assess short term and mid-term symptomatic changes. This study will use Dry Eye Surveys to evaluate Acoltremon in Real World Settings to help understand its real world effectiveness and potential to improve symptoms in dry eye patients.

Key Dates

Start date
Dec 15, 2025
Status verified
Dec 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: all subjects meeing inclusion/exclusion will be dispensed FDA Approved acoltremon
    all subjects meeing inclusion/exclusion will be dispensed FDA Approved acoltremon 0.003%

Primary Outcome Measure

• Mean Change in SPEED questionnaire score at 1 month (day 30 ± 3 days) [ Time Frame: Mean Change in SPEED questionnaire score at 1 month (day 30 ± 3 days) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Center for SightLas VegasNevada89128
Clinical Research Manager
[email protected]
702-724-2005
Clinical Research Coordinator
702-724-2067
Eva I Liang, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Las Vegas, NV

By research site
Center for Sight· Las Vegas, NV

Related Studies